Johnson & Johnson is cutting several programs—most of which are in neurology and psychiatry—as the company also pulls back from the infectious diseases market.

Here are eight key developments from spine and orthopedic devicemakers since Oct. 9. 1. Johnson & Johnson MedTech began the ...

On Tuesday, Johnson & Johnson (NYSE:JNJ) reported a third-quarter adjusted EPS of $2.42, down 9.0% year-over-year, beating ...

Q3 2024 Earnings Call Transcript October 15, 2024 Johnson & Johnson beats earnings expectations. Reported EPS is $2.42, ...

Third-quarter results exceeded estimates, but the company also lowered overall earnings expectations for 2024.

The Liberia Petroleum Refining Corporation (LPRC), under its new Managing Director, Amos Tweh, has implemented key measures to revitalize Liberia’s oil and gas sector and alleviate the economic strain ...

Good morning, and welcome to Johnson & Johnson's third-quarter 2024 earnings conference call. (Operator Instructions) This call is being recorded. If anyone has any objections, you may disconnect at ...

Wells Fargo analyst Larry Biegelsen maintained a Hold rating on Johnson & Johnson (JNJ – Research Report) today and set a price ...

Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on Johnson & Johnson (JNJ – Research Report), retaining the price ...

The company also revised its operational earnings forecast from $10.05 to $9.91. The V-Wave acquisition is expected to dilute ...

Johnson & Johnson beat investors’ expectations despite its medtech unit underperforming, with execs pointing to the Asia-Pacific region as a continued source of struggle. Executives said on the ...

TORONTO—While the FDA has already doled out green lights to about 950 medical devices backed by artificial intelligence or ...